Data from the phase I/II study of Rina-S (rinatabart sesutecan), an investigational folate receptor-alpha-targeted, Topo1 antibody-drug conjugate, demonstrated a confirmed objective response rate of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every three weeks, regardless of FRα expression levels.
A team led by researchers at the University of Chicago discovered how to block nicotinamide N-methyl transferase, an enzyme that is involved in the progression of high-grade serous ovarian cancer.
